Wikiwand AI

Deupsilocin

Serotonergic psychedelic From Wikipedia, the free encyclopedia

Deupsilocin (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; former developmental code names HLP003 and CYB0003), also known as deuterated psilocin or as psilocin-d10, is a psychedelic drug of the tryptamine family related to psilocin which is under development for the treatment of major depressive disorder, alcoholism, and other psychiatric disorders.[1][4][5][6][7][2][8] It is taken orally.[1] The drug is a deuterated isotopologue of psilocin with altered pharmacokinetics.[1][5][6][2]

Other namesPsilocin-d10; Psilocin-D10; HLP003; HLP-003; CYB003; CYB-003; Deuterated psilocybin analogue; Deuterated psilocin analogue; Deuterated psilocin; Decadeuteropsilocin
Routes of
administrationOral[1]
Drug classSerotonergic psychedelic; Hallucinogen[1][2]
Onset of action<15 minutes[3]
Quick facts Clinical data, Other names ...
Deupsilocin
Clinical data
Other namesPsilocin-d10; Psilocin-D10; HLP003; HLP-003; CYB003; CYB-003; Deuterated psilocybin analogue; Deuterated psilocin analogue; Deuterated psilocin; Decadeuteropsilocin
Routes of
administration		Oral[1]
Drug classSerotonergic psychedelic; Hallucinogen[1][2]
Pharmacokinetic data
Onset of action<15 minutes[3]
Duration of action4–6 hours[3]
Identifiers
  • 3-[2-[bis(trideuteriomethyl)amino]-1,1,2,2-tetradeuterioethyl]-1H-indol-4-ol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC12H16N2O
Molar mass204.273 g·mol−1
3D model (JSmol)
  • [2H]C([2H])([2H])N(C([2H])([2H])[2H])C([2H])([2H])C([2H])([2H])C1=CNC2=C1C(=CC=C2)O
  • InChI=1S/C12H16N2O/c1-14(2)7-6-9-8-13-10-4-3-5-11(15)12(9)10/h3-5,8,13,15H,6-7H2,1-2H3/i1D3,2D3,6D2,7D2
  • Key:SPCIYGNTAMCTRO-HXOHQZFQSA-N
Close

Interactions

See also: Psychedelic drug § Interactions, and Trip killer § Serotonergic psychedelic antidotes

Pharmacology

The pharmacodynamic profile of deupsilocin, including its interactions with serotonin receptors and its effects in animals, is similar to that of psilocin.[2] As with psilocin, deupsilocin is a potent agonist of the serotonin 5-HT2A receptor and produces psychedelic-like effects in animals.[2] However, it was developed to have improved pharmacokinetic properties compared to psilocybin, including reduced variability in circulating levels, a faster onset of action, and a shorter duration.[8]

In humans, deupsilocin has been reported to have 2.2-fold higher peak levels and 3.5-fold higher area-under-the-curve (AUC) levels than psilocybin at equivalent doses.[3] It is said to have a rapid onset of less than 15 minutes and a duration of 4 to 6 hours.[3]

Chemistry

Analogues

In addition to deupsilocin, Helus Pharma has also patented other deuterated psilocin isotopologues.[9] Other deuterated drugs related to deupsilocin include the deuterated dimethyltryptamine (DMT) isotopologues deudimethyltryptamine (HLP004; CYB004; DMT-d10; deudimethyltryptamine) and SPL028 (D2-DMT) and the deuterated phenethylamine HLP005 (CYB005).[5][10]

Research

In 2024, deupsilocin received a breakthrough therapy designation from the U.S. FDA[11] and was in phase 3 clinical trials for major depressive disorder and is in the preclinical stage of development for alcoholism and other psychiatric disorders.[1][4][12] Two phase 3 clinical trials for major depressive disorder are being initiated in November 2024 and February 2025.[1][4][12] The drug is under development by Helus Pharma (formerly Cybin).[1][4][12]

See also

References

External links

Related Articles

Timelines

Top Qs

Fact Checks